ArticlemedRxiv : the preprint server for health sciences2026
The national burden from O'nyong'nyong and chikungunya viruses in Cameroon.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
O'nyong-nyong (ONNV) and chikungunya (CHIKV) are arboviruses that have been identified nearly throughout Africa. However, the disease burden from the viruses has been rarely quantified as surveillance systems are poorly equipped to identify cases. Here, we tested 6,324 serum samples collected as part of the Yellow Fever testing program between 2010 and 2023 in individuals of all ages from all the health districts of Cameroon. We used a novel multiplex assay that incorporated antigens from three alphaviruses (ONNV, CHIKV and MAYV) and mathematical models that explicitly consider cross-reactivity to reconstruct individual and population infection histories for each virus. We found that despite no cases reported in Cameroon, ONNV has circulated endemically across the country for decades with an average of 332,000 annual infections and 8 million individuals with a history of infection. By contrast, we found evidence of only sporadic CHIKV outbreaks, with an estimated prevalence of 1.7%. Models that did not explicitly consider cross-reactivity between the alphaviruses lead to incorrect conclusions about the circulation of the viruses. This work highlights the need for systematic efforts to identify ONNV incident cases and the development of a vaccine development investment case against this neglected pathogen.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.